The Role of Changes in the Proportion of Fecal Short-Chain Fatty Acids on the Severity of Hepatic Encephalopathy in Cirrhosis Patients
Keywords:
SCFA, cirrhosis, hepatic encephalopathy, feces, dysbiosisAbstract
Background: Short-chain fatty acids (SCFA) are the main metabolites of the intestinal microbiota, which play a role as colonocyte trophic factors and maintain the integrity of the gastrointestinal tract and blood-brain barrier. Microbiota dysbiosis that occurs in cirrhosis reduces SCFA production and plays a role in the pathogenesis of hepatic encephalopathy (HE). This study aims to compare the amount and composition of fecal SCFA in patients with cirrhosis, with and without HE. Methods: This research is a cross-sectional study at the Hepatobiliary Clinic and Integrated Procedure Room, Dr. Cipto Mangunkusumo Hospital, Jakarta, in 2023. Patients with cirrhosis underwent a flicker or Stroop test, fecal SCFA examination (acetate, butyrate, and propionate), and a questionnaire with a food recall technique to assess dietary patterns. Results: A total of 86 patients with cirrhosis participated in this study, with a mean age of 53 ± 8.10 years, and the majority were male (68.6%). Hepatic encephalopathy (HE) was identified in 20 patients (23.25%). Multivariable analysis of SCFA profiles showed no statistically significant associations with HE. The absolute SCFA proportion had an adjusted prevalence ratio (PR) of 1.98 [95% CI: 0.75–5.24; p = 0.171], the absolute acetate proportion had an adjusted PR of 2.06 [95% CI: 0.40–10.62; p = 0.388], and the butyrate proportion had an adjusted PR of 2.02 [95% CI: 0.76–5.39; p = 0.158]. Conclusion: Changes in SCFA composition may be associated with the presence of HE in patients with cirrhosis. Although no statistically significant relationships were found, these findings suggest that SCFA profiles warrant further investigation concerning dysbiosis and HE in cirrhosis.References
Ferenci P. Hepatic encephalopathy. Gastroenterol Rep. 2017 May;5(2):138–47.
Hadjihambi A, Arias N, Sheikh M, et al. Hepatic encephalopathy: a critical current review. Hepatol Int. 2017 Aug 2;12(Suppl 1):135–47.
Hasan I, Araminta A. Ensefalopati hepatik: apa, mengapa, dan bagaimana? Medicinus. 2014 Desember;27(3):1–8.
de la Cuesta-Zuluaga J, Mueller NT, Álvarez-Quintero R, et al. Higher Fecal Short-Chain Fatty Acid Levels Are Associated with Gut Microbiome Dysbiosis, Obesity, Hypertension and Cardiometabolic Disease Risk Factors. Nutrients. 2018 Dec 27;11(1):51.
Tan C, Wu Q, Wang H, et al. Dysbiosis of gut microbiota and short‐chain fatty acids in acute ischemic stroke and the subsequent risk for poor functional outcomes. JPEN J Parenter Enteral Nutr. 2021 Mar;45(3):518–29.
Silva YP, Bernardi A, Frozza RL. The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain Communication. Front Endocrinol [Internet]. 2020 [cited 2022 Nov 29];11. Available from: https://www.frontiersin.org/articles/10.3389/fendo.2020.00025
Bloom PP, Luévano JM, Miller KJ, et al. Deep stool microbiome analysis in cirrhosis reveals an association between short-chain fatty acids and hepatic encephalopathy. Ann Hepatol. 2021 Nov;25:100333.
Clausen MR, Mortensen PB, Bendtsen F. Serum levels of short-chain fatty acids in cirrhosis and hepatic coma. Hepatol Baltim Md. 1991 Dec;14(6):1040–5.
Hasan N, Yang H. Factors affecting the composition of the gut microbiota, and its modulation. PeerJ. 2019 Aug 16;7:e7502.
Wen L, Duffy A. Factors Influencing the Gut Microbiota, Inflammation, and Type 2 Diabetes. J Nutr. 2017 Jul;147(7):1468S-1475S.
Riggio O, Ridola L, Pasquale C. Hepatic encephalopathy therapy: An overview. World J Gastrointest Pharmacol Ther. 2010 Apr 6;1(2):54–63.
Darnindro N, Manurung A, Mulyana E, et al. Clinical Characteristics of Liver Cirrhosis Patients in Internal Medicine Inpatient Ward of Fatmawati General Hospital and Factors Affecting Mortality during Hospitalization. Indones J Gastroenterol Hepatol Dig Endosc. 2021 May 12;22(1):3–8.
Kalista KF, Lesmana CRA, Sulaiman AS, et al. Clinical profile of cirrhotic patients with esophageal varices who have undergone band ligation in Cipto Mangunkusumo Hospital. J Penyakit Dalam Indones. 2019;6(1):7.
Brůha R, Jachymova M, Petrtyl J, et al. Osteopontin: A non-invasive parameter of portal hypertension and prognostic marker of cirrhosis. World J Gastroenterol. 2016 Mar 28;22:3441–50.
Xie W, Cao Y, Xu M, et al. Prognostic Significance of Elevated Cholestatic Enzymes for Fibrosis and Hepatocellular Carcinoma in Hospital Discharged Chronic Viral Hepatitis Patients. Sci Rep. 2017 Dec 1;7.
Maggi DC, Borgonovo A, Bansho ET, et al. Serial assessment of hepatic encephalopathy in patients hospitalised for acute decompensation of cirrhosis. Ann Hepatol. 2019 Mar 1;18(2):331–7.
Cao X, Zolnikova O, Maslennikov R, et al. Differences in Fecal Short-Chain Fatty Acids between Alcoholic Fatty Liver-Induced Cirrhosis and Non-alcoholic (Metabolically Associated) Fatty Liver-Induced Cirrhosis. Metabolites. 2023 Jul;13(7):859.
Roy CC, Kien CL, Bouthillier L, et al. Short‐chain fatty acids: ready for prime time? Nutr Clin Pract. 2006 Aug;21(4):351–66.
Jin M, Kalainy S, Baskota N, et al. Faecal microbiota from patients with cirrhosis has a low capacity to ferment non‐digestible carbohydrates into short‐chain fatty acids. Liver Int. 2019 Aug;39(8):1437–47.
Wu Z, Zhou H, Liu D, et al. Alterations in the gut microbiota and the efficacy of adjuvant probiotic therapy in liver cirrhosis. Front Cell Infect Microbiol [Internet]. 2023 [cited 2024 Feb 18];13. Available from: https://www.frontiersin.org/articles/10.3389/fcimb.2023.1218552
Trebicka J, Macnaughtan J, Schnabl B, et al. The microbiota in cirrhosis and its role in hepatic decompensation. J Hepatol. 2021 Jul 1;75:S67–81.
Fusco W, Lorenzo MB, Cintoni M, et al. Short-chain fatty-acid-producing bacteria: key components of the human gut microbiota. Nutrients. 2023 May 6;15(9):2211.
Gerrior S, Juan W, Peter B. An easy approach to calculating estimated energy requirements. Prev Chronic Dis. 2006 Sep 15;3(4): A129.
Saleh ZM, Salim NE, Nikirk S, et al. Burden of cirrhosis on patients and caregivers. Hepatol Commun. 2022 Jul 6;6(10):2827–35.
Volk ML. The emotional burden of caregiving for patients with cirrhosis. Hepatol Commun. 2020 Aug;4(8):1107.
Park JH, Kang M, Jun DW, et al. Determining whether low protein intake (<1.0 g/kg) is a risk factor for malnutrition in patients with cirrhosis. J Clin Med [Internet]. 2021 May [cited 2024 Feb 21];10(10). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8156669/
Nielsen K, Kondrup J, Martinsen L, et al. Long-term oral refeeding of patients with cirrhosis of the liver. Br J Nutr. 1995 Oct;74(4):557–67.
Dhaliwal A, Armstrong MJ. Sarcopenia in cirrhosis: A practical overview. Clin Med. 2020 Sep;20(5):489–92.
Louissaint J, Deutsch-Link S, Tapper EB. Changing epidemiology of cirrhosis and hepatic encephalopathy. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2022 Aug;20(8 Suppl):S1–8.
Tapper EB, Zhao L, Nikirk S, et al. The incidence and bedside predictors of the first episode of overt hepatic encephalopathy in patients with cirrhosis. Am J Gastroenterol. 2020 Dec;115(12):2017–25.
Wang Q, Chen C, Zuo S, et al. Integrative analysis of the gut microbiota and faecal and serum short-chain fatty acids and tryptophan metabolites in patients with cirrhosis and hepatic encephalopathy. J Transl Med. 2023 Jun 17;21(1):395.
Tan J, McKenzie C, Potamitis M, et al. The Role of Short-Chain Fatty Acids in Health and Disease. In: Advances in Immunology [Internet]. Elsevier; 2014 [cited 2022 Dec 8]. p. 91–119. Available from: https://linkinghub.elsevier.com/retrieve/pii/B9780128001004000039
Van Der Hee B, Wells JM. Microbial regulation of host physiology by short-chain fatty acids. Trends Microbiol. 2021 Aug;29(8):700–12.
Garcia-Bonete MJ, Rajan A, Suriano F, et al. The Underrated Gut Microbiota Helminths, Bacteriophages, Fungi, and Archaea. Life. 2023 Aug 18;13(8):1765.
Fitriakusumah Y, Lesmana CRA, Bastian WP, et al. The role of Small Intestinal Bacterial Overgrowth (SIBO) in Non-alcoholic Fatty Liver Disease (NAFLD) patients evaluated using Controlled Attenuation Parameter (CAP) Transient Elastography (TE): a tertiary referral center experience. BMC Gastroenterol. 2019 Mar 20;19(1):43. doi: 10.1186/s12876-019-0960-x. PMID: 30894137; PMCID: PMC6427876.
Jasirwan COM, Muradi A, Hasan I, et al. Correlation of gut Firmicutes/Bacteroidetes ratio with fibrosis and steatosis stratified by body mass index in patients with non-alcoholic fatty liver disease. Biosci Microbiota Food Health. 2021;40(1):50-58. doi: 10.12938/bmfh.2020-046. Epub 2020 Sep 15. PMID: 33520569; PMCID: PMC7817510.
Astari D, Lesmana CRA, Simadibrata MK. Correlation of short-chain fatty acid (SCFA) levels with transient elastography values and controlled attenuation parameters in non-alcoholic fatty liver disease (NAFLD) patients. Jakarta: Internal Medicine Study Program; 2023. T23492fk. xvi, 56 pages; 21x30 cm.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Mochamad Anief Ferdianto, Juferdy Kurniawan
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright
The authors who publish in this journal agree to the following requirements:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)
Privacy Statement
The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.
